Genomic Testing Cooperative

Genomic Testing Cooperative State-of-the-art Innovation
Machine/deep Learning meets Next Generation Sequencing

Don’t let QNS/TNP fears stop you from ordering comprehensive genomic profiling.Using innovative chemistry helps reduce Q...
04/23/2026

Don’t let QNS/TNP fears stop you from ordering comprehensive genomic profiling.

Using innovative chemistry helps reduce QNS and TNP rates. GTC's QNS rate is currently less than 1%. Most labs using NGS are greater than >10% QNS/TNP

Read more: https://genomictestingcooperative.com/genomic-tests/

When patients present with neurologic symptoms suggestiveof leptomeningeal disease (LMD), timely and accurate molecular ...
04/22/2026

When patients present with neurologic symptoms suggestive
of leptomeningeal disease (LMD), timely and accurate molecular insight can be
critical. Traditional diagnostics—CSF cytology, imaging, and plasma-based
testing—often lack sensitivity in this setting.

Liquid Trace® on CSF is designed to address these gaps:
· Higher tumor signal than plasma for CNS-confined disease due to the blood–brain barrier
· Improved detection when cytology is negative or equivocal
· Comprehensive genomic profiling from limited CSF input, supporting therapy selection
· Actionable insights for
metastatic and primary CNS malignancies using a single assay
· Clinically practical when tissue is unavailable or unsafe to obtain

Liquid Trace™ On Cerebral Spinal Fluid (CSF) | Genomic Testing Cooperative

Visit GTC at AACR
04/21/2026

Visit GTC at AACR

Happy Lab Week to the incredible team at GTC! 🧬 This week, we’re celebrating the people behind the science with team lun...
04/20/2026

Happy Lab Week to the incredible team at GTC! 🧬 This week, we’re celebrating the people behind the science with team lunches, fun events, and well-deserved recognition. Your dedication to delivering high-quality, impactful results makes a difference for patients every day. Thank you for all that you do!

GTC’s Multiple Myeloma testing goes beyond diagnosis: with Liquid Trace Hematology, we monitor treatment response, visua...
04/17/2026

GTC’s Multiple Myeloma testing goes beyond diagnosis: with Liquid Trace Hematology, we monitor treatment response, visualize variant allele frequency (VAF) trends over time, and detect secondary neoplasms as they emerge. Our assays also identify co-existing hematologic conditions, distinguish NSD2 disruption timing for prognostic implications, and determine clonotypes for longitudinal disease tracking.

https://genomictestingcooperative.com/genomic-tests/liquid-trace-hematologic-malignancies/

Head and neck cancers are complex diseases that often require precise molecular insight to guide treatment decisions. Co...
04/17/2026

Head and neck cancers are complex diseases that often require precise molecular insight to guide treatment decisions. Comprehensive genomic profiling can help identify clinically relevant mutations, gene fusions, and emerging RNA-based targets that may inform therapy selection and clinical trial options.

At Genomic Testing Cooperative (GTC), our testing analyzes both DNA and RNA, enabling detection of alterations that may be missed with DNA-only approaches. By providing a deeper molecular understanding of each tumor, we help clinicians make more informed decisions for patients facing head and neck cancer.

Learn more: https://genomictestingcooperative.com/genomic-tests/solid-tumor-profile-plus/

Visit us at Booth #1860 to explore how our advanced RNA and cfRNA profiling unlocks deeper biological insight beyond DN...
04/16/2026

Visit us at Booth #1860 to explore how our advanced RNA and cfRNA profiling unlocks deeper biological insight beyond DNA—enabling detection of fusions, splice variants, and dynamic tumor signaling from both tissue and blood.

Our pharma services platform supports:
• Biomarker discovery & validation
• Clinical trial stratification
• Longitudinal monitoring with cfRNA

https://genomictestingcooperative.com/research-pharma-services/

GTC’s deep sequencing (>2500 read depth on tissue and BM and >25,000 read depth on liquid biopsy) enables detection of l...
04/15/2026

GTC’s deep sequencing (>2500 read depth on tissue and BM and >25,000 read depth on liquid biopsy) enables detection of low-frequency variants, fusions, and splice events that standard approaches may miss—delivering a more complete molecular picture.

The result: greater sensitivity, fewer false negatives, and higher confidence in every report—so you can make informed clinical decisions when it matters most.

Don't accept partial results!

https://genomictestingcooperative.com/genomic-tests/



Address

25371 Commercentre Drive
Lake Forest, CA
92630

Telephone

+19495409421

Website

Alerts

Be the first to know and let us send you an email when Genomic Testing Cooperative posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Genomic Testing Cooperative:

Shortcuts

Share

Category